Nov. 18, 2026
CAMBRIDGE, MASSACHUSETTS — Skylark Bio announced that an independent Data Safety Monitoring Board (DSMB) has unanimously recommended advancing its investigational gene therapy, SKY-GJB2, into the next stage of the SONIX Phase 1/2 clinical trial. The decision follows a review of safety data from the first four children treated in the study, allowing researchers to begin enrolling younger participants. The next cohort
















